Quarterly ResultAug 5, 2026, 09:31 AM
Charles River Labs Q2 Net Loss $1.48M; Revenue Down
AI Summary
Charles River Laboratories reported a net loss attributable to common shareholders of $1.48 million for the second quarter of 2026, a significant decline from a net income of $52.33 million in the prior year. Total revenue decreased slightly to $1.004 billion from $1.032 billion. The company completed two acquisitions, PathoQuest SAS for $67.6 million and K.F. Cambodia for $507.3 million, while divesting its European Discovery Services businesses for $125.2 million and CDMO and Cell Solutions businesses, incurring a pre-tax loss of $63.7 million on the latter.
Key Highlights
- Q2 net loss attributable to common shareholders was $(1.48) million.
- Q2 total revenue decreased to $1.004 billion from $1.032 billion year-over-year.
- Acquired K.F. Cambodia for $507.3 million in January 2026.
- Acquired PathoQuest SAS for $67.6 million in April 2026.
- Divested European Discovery Services for $125.2 million cash.
- Divested CDMO and Cell Solutions, incurring a $63.7 million pre-tax loss in Q2.
- Net cash provided by operating activities for six months was $220.8 million.
- Long-term debt increased to $2.62 billion from $2.14 billion.